(Q46597192)

23 December 2017

title

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors (English)

1 reference

23 December 2017

1 reference

3

Markus W Büchler

1 reference

23 December 2017

7

Helmut Friess

1 reference

23 December 2017

1

Moritz N Wente

1 reference

23 December 2017

author name string

Jörg Kleeff

2

1 reference

23 December 2017

Jantien Wanders

4

1 reference

23 December 2017

Peter Cheverton

5

1 reference

23 December 2017

Stephen Langman

6

1 reference

23 December 2017

publication date

1 August 2005

1 reference

23 December 2017

Investigational New Drugs

published in

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

339-347

1 reference

23 December 2017

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-1442-2

Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-005-1442-2

Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I

21 January 2018

1 reference

12 December 2020

Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

1 reference

12 December 2020

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

1 reference

12 December 2020

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients

1 reference

12 December 2020

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

1 reference

12 December 2020

CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data

1 reference

12 December 2020

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

1 reference

12 December 2020

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

12 December 2020

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

1 reference

12 December 2020

DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

1 reference

12 December 2020

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

1 reference

12 December 2020

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer

1 reference

12 December 2020

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

1 reference

12 December 2020

DX-8951f: summary of phase I clinical trials

1 reference

12 December 2020

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

1 reference

12 December 2020

Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog

1 reference

12 December 2020

Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks

1 reference

12 December 2020

Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices

1 reference

12 December 2020

Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.

1 reference

12 December 2020

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors

1 reference

12 December 2020

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies

1 reference

12 December 2020

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies

1 reference

12 December 2020

DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant

1 reference

12 December 2020

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks

1 reference

12 December 2020

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum

1 reference

12 December 2020

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

12 December 2020

Tumoritropic and lymphotropic principles of macromolecular drugs

1 reference

12 December 2020

Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

1 reference

12 December 2020

Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model

1 reference

12 December 2020

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

1 reference

12 December 2020

10.1007/S10637-005-1442-2

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017